Day 1 Program

Rapid Fire 2

Day 1: December 9, 2025

5:45 PM–6:45 PM CST

Stars at Night 1-2

Session Details

Oral presentations of high impact clinical trials and scientific discovery.
The text of the abstracts will be posted on Monday, November 24.

Moderator

Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN

RF2-01

Prognostic Markers in Residual Tumors after neoadjuvant chemotherapy (NACT) for Early Triple-negative Breast Cancer (TNBC) – a Pooled Analysis from nine Neoadjuvant GBG/AGO-B Trials

Johannes Holtschmidt, GBG c/o GBG Forschungs GmbH, Neu Isenburg, Germany

RF2-02

Pooled analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto clinical trials identifies the impact of neoadjuvant carboplatin on pCR and survival in early-stage triple-negative breast cancer

Brooke M Felsheim, University of North Carolina at Chapel Hill, Chapel Hill, NC

RF2-03

Adjuvant epirubicin plus cyclophosphamide followed by taxanes with or without carboplatin for early stage triple-negative breast cancer (RJBC 1501): a randomized controlled phase III trial

Xiaosong Chen, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

RF2-04

Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high-risk early-stage triple-negative breast cancer (CITRINE): a phase 3 randomized trial

Yin Liu, Fudan University Shanghai Cancer Center, Shanghai, China

RF2-05

Discussant for RF2-03 and RF2-04

Priyanka Sharma, University of Kansas Medical Center, Kansas City, KS

RF2-06

Impact of Immune Checkpoint Inhibition (CPI) on Fertility in Young Women with Early Triple-Negative Breast Cancer (TNBC) receiving neoadjuvant Chemotherapy (NACT): A Prospective Substudy of the NSABP B-59/GBG-96-GeparDouze Trial

Mattea Reinisch, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany

RF2-07

Nodal disease burden in patients with clinically node-positive breast cancer undergoing tailored axillary surgery with or without axillary dissection in the neoadjuvant and upfront surgery setting: pre-planned TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)

Walter P. Weber, University of Basel, Basel, Switzerland & Breast Clinic, University Hospital Basel, Basel, Switzerland